Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022🗂️ Report periods on file: 2022, 2021, 2020, 2019, 2017, 2016

In its 2022 reporting, Chunghwa Chemical Synthesis & Biotech Co., Ltd. disclosed greenhouse gas emissions of 15.9K tCO2e/year. By scope: Scope 1: 4.0K tCO2e/year; Scope 2: 11.9K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
15.9K tCO2e/year
2022
💧
Water Usage
83.2K tons/year
2022
♻️
Waste
2.1K tons/year
2022

📊 Emissions by Scope (2022)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).4.0K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.11.9K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
202215.9K tCO2e/year
202114.1K metric tons (tCO2e)
202011.9K tCO2e/year
201912.6K tCO2e/year
201712.3K tCO2e/year
201613.2K tCO2e/year (Scope 1 & 2)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce electricity consumption by over 1% annually.
  • Implement six vacuum pump water recovery systems.

📅 Medium-term

  • Improve manufacturing technology, adding hydrogenation and metal reactions.
  • Expand CDMO/CMO business.

🔭 Long-term

  • Develop high-priced, high-tech products with few competitors.
  • Develop unique key technologies for special products (anti-cancer, high potency, peptide drugs).

🌱 ESG Focus Areas

Environmental protectionEmployee well-beingCorporate governance

⚠️ Challenges & Risks +

  • Sensitivity to US dollar exchange rate fluctuations.
  • Low-cost competition from Chinese and Indian API manufacturers.
  • Stringent inspection requirements from US and EU pharmaceutical authorities.
  • Uncertainties in the growth of generic pharmaceutical markets due to supply chain disruptions, inflation, and geopolitical risks.

📋 Report Information

Reporting Period: 2022
Frameworks: GRI Standards